source
- Amgen tightens 340B program rules, expanding pharmacy claims data requirementsAmgen announced it is expanding the data it requires from pharmacies that dispense its products under the federal 340B drug discount program. The new policy will obligate participating pharmacies…
- Aardvark to unblind rare disease trial after FDA places full clinical hold; Alumis issues verdict on Acelyrin assetAardvark's rare disease candidate is under a full clinical hold by the FDA, which has paused all dosing and data collection. The company says it intends to unblind the trial data despite the hold,…